Sentences with phrase «of resistance to these therapies»

Not exact matches

I won't reveal yet who my favorites are, but I will say that these young scientist - founders came up with very creative solutions for preventing infections in some common surgeries, tackling resistance in targeted antibody drugs, improving gene vectors for cell therapies, helping the vision - impaired «see» faces and better read their environments, imaging hard - to - see spots in the lungs and other organs, improving genetic risk analysis, and expediting the logistical operations of hospitals.

They note that targeting inflammation to treat infections offers an advantage over antibiotic therapy, as the former hinders gene transfer and the evolution of pathogens, while the latter promotes bacterial evolution and, ultimately, antibiotic resistance.

Now a University of Colorado Cancer Center study published online ahead of print in the journal Oncogene offers compelling evidence explaining this failure and offering a possible strategy for the use of retinoic acid or other retinoids against some breast cancers: Because early clinical trials are often offered to patients who have already tried other more established therapies, breast cancer cells may have been pushed past an important tipping point that offers retinoic acid resistance.

The study «provided the surprising result that one new therapy currently being explored to lower insulin resistance promotes, rather than decreases, the formation of bone in mice,» says Darwin Prockop, a stem cell researcher at Texas A&M College of Medicine in Temple, who was not involved in the work.

Tissue engineering provides a more practical means for researchers to study cell behavior, such as cancer cell resistance to therapy, and test new drugs or combinations of drugs to treat many diseases.

The analysis suggests that alternative therapies for certain mild infections — which may be easier to develop — could indirectly slow development of antibiotic resistance in more dangerous bugs.

They have also discovered that a protein named Wnt5A promotes metastatic progression, resistance to therapy and poorer prognosis, and one of the ways in which it is regulated is by the anti-aging protein Klotho.

The researchers predict that the Thailand border area, which has used the artemisinin - based therapy since the mid-1990s, will see these levels of resistance within the next two to six years.

My cancer systems biology team at the University of California, Merced, is tackling diagnosis and treatment of therapy - resistant cancers by elucidating the network of changes within cells as a way to identify new drug targets and circumvent cancer resistance.

However, resistance to therapy might go beyond cancer mutations that usually alter the function of genes.

While the combination of targeted therapies improves patient outcomes, any remaining cancer cells can lead to drug resistance.

«This is a step forward in understanding pancreatic cancer's resistance to standard therapies,» said principal investigator Gregory Beatty, MD, PhD, an assistant professor of Hematology / Oncology at Penn and a member of Penn's Abramson Cancer Center.

«We believe this discovery is a promising avenue for developing a new therapy to reduce chemo - resistance in women with this deadly disease,» said Dr. Dar - Bin Shieh, collaborative partner from National Cheng Kung University of Taiwan.

Sometimes they respond to renewed treatment, but then develop a resistance against all methods of therapy.

This discovery is an important step in the personalisation of the treatment of colorectal cancer, as the presence of this mutation is associated with an increased resistance compared to standard therapies.

«Considering that frequent amplification of MET accounts for resistance to therapies now in development and to poor prognosis, not only in ovarian cancer but in other cancers too, our findings pinpoint an important new signaling hub, involving the role of FER in MET activation.

«One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum - resistant patients with recurrent or persistent disease,» said Robert L. Coleman, MD, lead author of the study and professor and vice chair of clinical research at the University of Texas MD Anderson Cancer Center, Houston.

Just as chemotherapy often requires several drugs to combat resistance in cancerous cells, successful antimicrobial therapy against some pathogens requires a combination of drugs.

The threat of antibiotic resistance is nothing to scoff at: The World Health Organization predicts (pdf) that some diseases, including malaria, tuberculosis, and pneumonia, could have «no effective therapies within the next 10 years.»

Until RDTs became widespread, almost all fevers were treated as if they were malaria, leading to the overuse of the new generation of «wonder drugs,» artemisinin - based combination therapies (ACTs), which were in danger of being lost to drug resistance.

Cancer stem cells are strongly associated with the growth and recurrence of all cancers and are especially difficult to eradicate with normal treatment, which also leads to tumours developing resistance to other types of therapy.

«There has been a groundswell of interest in the idea of reversing resistance to androgen deprivation therapy.

They enabled health workers in remote villages in Africa and Asia to accurately and almost instantly diagnose malaria, making them less likely to overuse the new generation of «wonder drugs,» artemisinin - based combination therapies (ACTs), which were in danger of being lost to drug resistance.

This high mortality is primarily caused by resistance to therapy and the diagnosis of ovarian cancer after it has already metastasized, which occurs in approximately 80 percent of patients.

The emphasis now is to store samples from almost every major study with correlative science in mind, and this is essential if we are to understand disease biology, mechanism of response and resistance to therapy in the era of targeted therapy and precision medicine.»

«By helping us understand that lower levels of RNF125 confer resistance to BRAF inhibitors, we have a new strategy to stratify patients for currently approved therapy versus participation for human clinical trials to investigate whether targeting JAK1 will be more effective in patients whose tumors exhibit reduced RNF125,» said Keith T. Flaherty, M.D., associate professor, Harvard Medical School, and director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital, and co-author of the study.

Loss of the tumor suppressor p53 often contributes to therapy resistance in tumors.

In their report that has received advance online publication in Nature Nanotechnology, a research team based at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) describes how a nanomedicine that combines photodynamic therapy — the use of light to trigger a chemical reaction — with a molecular therapy drug targeted against common treatment resistance pathways reduced a thousand-fold the dosage of the molecular therapy drug required to suppress tumor progression and metastatic outgrowth in an animal model.

«The over-prescribing of anti-malarials puts evolutionary pressure on the malaria parasite that risks hastening its resistance to artemisinin - based combination therapy — the frontline drugs used to treat malaria in Africa,» Stoler said.

The other study — Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma — published March 30, shows how drugs targeting PI3K and MAPK could represent promising candidates for glioblastoma therapy.

«Resistance to hormonal therapy is a major clinical problem in the treatment of most breast cancers.

As a clinician - scientist with a translational research focus, Dr. Deininger is heading an extramurally funded research laboratory that is dedicated to the study of signaling pathways, drug resistance, and new molecular therapies in leukemia.

This finding is of particular concern, Murakami says, because if the bacterium is not eradicated after the recommended therapy, it could indicate potential resistance to drugs of choice.

Field reports suggest that not all K13 mutations are capable of causing resistance, and the genetic system developed by Dr. Fidock to study K13, based on DNA repair approaches that are being used in human gene therapy studies, will be critical in identifying real hot spots of resistance.

Though malaria deaths have dropped by 30 percent worldwide since the introduction of artemisinin - based combination therapies (ACTs) in the late 1990s, these gains are now threatened by the emergence of resistance to the core artemisinin component of ACTs in Southeast Asia.

Gene therapy could impart this kind of resistance to others.

The tumors often develop resistance to existing therapies, and in general only 50 % of people with the cancer live longer than 15 months.

«Globally, resistance to some strains of pneumonia is increasing, so it is imperative to increase development in the R&D pipeline of new antibacterial therapies, especially infections that are acquired in - hospitals, where the pathogens are highly resistant.»

However, these patients will eventually develop resistance to EGFR TKI therapy and a further EGFR mutation called T790M accounts for 60 % of this acquired resistance.

And while new therapies have been effective in releasing the immune system's restraints to unleash the body's own cancer - fighting powers, they only work in about half of melanoma patients and often lose their potency as the cancer develops resistance.

The study also adds to our understanding of disease development and therapy resistance,» Theodorescu says.

«This may be compensatory and a mechanism of resistance to anti-psoriasis therapy, and it suggests that the solenopsin compounds could be used in combination with existing approaches,» Arbiser says.

«Current therapies take advantage of this by using targeted drugs such as Trastuzumab or Lapatinib to specifically inhibit ERBB2, but eventually they become ineffective as the cancer develops resistance to those drugs.»

«Understanding how the drugs work gives us the opportunity to investigate new treatments, for example by using combination therapies, or altering the dosage and timing of treatment to prevent drug resistance from emerging,» Dr Glaser said.

«Using a novel model we developed to facilitate discoveries about the growth and spread of lymph node metastases, we show that angiogenesis does not occur in lymph node metastases, providing a mechanism for resistance to angiogenic therapy in these situations.»

Shokat and his colleagues wanted to get ahead of this problem, and began thinking about third - generation mTOR inhibitors without waiting for patients to develop resistance to the latest therapies.

«Figuring out why resistance to targeted therapies develops has been the focus of our research for a long time,» says Paul Mischel, the paper's co-corresponding author, at the Ludwig Institute for Cancer Research at the University of California, San Diego.

Researchers developed the strategy as a way to develop inhibitors of «undruggable» proteins and overcome drug resistance, a common shortcoming of targeted therapies.

This visual abstract depicts how Wei et al. utilize single - cell phosphoproteomic analysis of patient derived glioblastoma models to identify shifts in signaling coordination following short - term treatment with kinase inhibitors, which facilitates the design of combination therapy approaches with reduced resistance and improved efficacy.

«We have previously demonstrated the role of MDSCs as important mediators of resistance to immune therapy approaches.